We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Novel Neuromuscular Junction Model Benefits Drug Discovery
Industry Insight

Novel Neuromuscular Junction Model Benefits Drug Discovery

Novel Neuromuscular Junction Model Benefits Drug Discovery
Industry Insight

Novel Neuromuscular Junction Model Benefits Drug Discovery

Credit: Pixabay

Want a FREE PDF version of This Industry Insight?

Complete the form below and we will email you a PDF version of "Novel Neuromuscular Junction Model Benefits Drug Discovery"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

The first functional stem-cell derived neuromuscular junction model has recently been licensed, which could help the quest to develop new drugs to treat associated neurodegenerative diseases. We caught up with James Hickman, CSO, Hesperos, to learn more about the microfluidic model, and some of the benefits it brings.

Anna MacDonald (AM): What is the function of neuromuscular junctions, and why are they an important system to study?

James Hickman (JH): Neuromuscular junction (NMJ) is the synaptic connection between motoneurons and skeletal muscle. It is an important system to study because it is critical for our ability to move: motoneurons control the activity of skeletal muscles through NMJs. Any impairment of NMJ can cause motor deficits, which has been found in diseases such as amyotrophic lateral sclerosis (ALS) and myasthenia gravis.

AM: What are some of the challenges of studying NMJs, and limitations of current methods?

James Hickman:
It has been challenging to study NMJs because there have been no efficient human-based in vitro NMJ models, nor any functional platforms that allow chronic (long-term) monitoring and analyzing NMJ function at high resolution.

It has been difficult to create such systems because the formation of NMJs is a very articulated process that requires the integrity of both motoneurons and skeletal muscles, as well as the proper interactions between them. It requires well-designed cell culture conditions to reproduce this process in vitro.

Currently, there are very limited selections of human-based NMJ models in which motoneuron stimulation can induce muscle contraction. Further, NMJ function has been analyzed by activating motoneurons with glutamate or optogenetics while monitoring muscle excitation by calcium imaging or patch clamp. These are very invasive, labor-intensive methods, and can have low temporal resolution.

AM: Can you tell us about the recently developed BioMEMs platform, and the benefits it can bring?

James Hickman: In our recently developed BioMEMs platform, motoneurons and muscle cells derived from human stem cells are partitioned in isolated PDMS chambers, separated by microtunnels that only allow motor axons to cross though. NMJ function is analyzed by stimulating motoneurons electrically, and muscle contractions are monitored with phase imaging differentials.

This platform can bring several advantages. It’s a fully human-based system with functional NMJ formation that can analyze NMJ function at high temporal resolution. It is also less invasive, allowing chronic monitoring of NMJ function.

AM: How is the platform being used to advance drug testing?

James Hickman: This system allows evaluation of dose response of drugs due to its high resolution in functional testing. In addition, because of the physical and electrical isolation of motoneurons and skeletal muscles in PDMS chambers, this system also allows the drug target analysis by applying the drug to correspondent chambers, but most importantly, because it is non-invasive it can be used to measure chronic effects.

AM: What future work do you have planned?

James Hickman: We will be adapting the platform to additional disease models, which can then be applied to drug screening or etiological study. There may also be applications for precision medicine, by introducing motoneurons or muscle derived from patient iPSCs.

James Hickman was speaking to Anna MacDonald, Science Writer for Technology Networks.

Meet The Author
Anna MacDonald
Anna MacDonald
Science Writer
Advertisement